Tech Company Financing Transactions
Rejuvenate Bio Funding Round
On 7/2/2024, Rejuvenate Bio secured $4 million in investment from California Institute for Regenerative Medicine.
Transaction Overview
Company Name
Announced On
7/2/2024
Transaction Type
Debt
Amount
$4,000,000
Round
Undisclosed
Proceeds Purpose
The company intends to use the funds to complete its IND-enabling activities for the development of RJB-0402 for the treatment of desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM).
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
3560 Dunhill St.
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Undisclosed
Website
Email Address
Overview
At Rejuvenate Bio, we are developing novel therapies to treat aging and age-related diseases through innovative targeted gene therapies. We launched out of George Church's lab at Harvard Medical School and the Wyss Institute for Biologically Inspired Engineering at Harvard University.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniel Oliver
Chief Medical Officer
Deborah Ascheim
Chief Scientific Officer
Noah Davidsohn
Co-Founder
George Church
Browse more venture capital transactions:
Prev: 7/1/2024: Pieces for Developers venture capital transaction
Next: 7/2/2024: Pi Squared venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs